71
Participants
Start Date
September 15, 2011
Primary Completion Date
February 21, 2013
Study Completion Date
February 21, 2013
AQW051
Patients will receive AQW051 in a high dose once daily orally for 28 days.
AQW051
Patients will receive AQW051 in a low dose once daily orally for 28 days.
Placebo
Patients will receive placebo once daily orally for 28 days.
Novartis Investigative Site, Berlin
Novartis Investigative Site, Manhasset
Novartis Investigative Site, Marseille
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Pessac
Novartis Investigative Site, Kassel
Novartis Investigative Site, Montpellier
Novartis Investigative Site, Marburg
Novartis Investigative Site, Nantes
Novartis Investigative Site, Cleveland
Novartis Investigative Site, Cincinnati
Novartis Investigative Site, Lille
Novartis Investigative Site, Clermont Fd
Novartis Investigative Site, Strasbourg
Novartis Investigative Site, Bron
Novartis Investigative Site, Tübingen
Novartis Investigative Site, Paris
Novartis Investigative Site, München
Novartis Investigative Site, Haag
Novartis Investigative Site, Poitiers
Novartis Investigative Site, Sacramento
Novartis Investigative Site, Dresden
Novartis Investigative Site, Gera
Novartis Investigative Site, Roma
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY